Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (15)	8/7/2000 9:19:32 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 508

Right. They just bought Japan rights. Related Quotes biz.yahoo.com Thursday August 3, 7:01 am Eastern Time Press Release InterMune Acquires Rights to Commercialize ACTIMMUNE In Japan for Infectious Diseases and Chronic Granulomatous Disease and Osteopetrosis BURLINGAME, Ca.--(BW HealthWire)--August 3, 2000--InterMune Pharmaceuticals, Inc. (Nasdaq: ITMN - news) announced today that it has licensed from Genentech, Inc. (NYSE: DNA - news) the exclusive rights to commercialize ACTIMMUNE® in Japan for the treatment and prevention of all infectious diseases and the treatment and prevention of infections in persons with chronic granulomatous disease (CGD) or osteopetrosis. Currently, InterMune markets ACTIMMUNE® in the United States for reducing the frequency and severity of serious infections associated with CGD. The license requires InterMune to pay royalties to Genentech on all sales in Japan. Prior to obtaining these additional commercialization rights, InterMune had the exclusive rights to commercialize ACTIMMUNE® in Japan for the treatment and prevention of infectious tuberculosis. ``These rights provide us with the opportunity to commercialize ACTIMMUNE® in Japan for infectious diseases and to seek the Japanese government's approval of ACTIMMUNE® for CGD. In addition, we'll be able to leverage our current CGD development efforts in the United States and regulatory and commercial development efforts for ACTIMMUNE® in Japan for multiple-drug resistant tuberculosis,'' stated W. Scott Harkonen, M.D., President and Chief Executive Officer of InterMune.